Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.
about
Denosumab: mechanism of action and clinical outcomesElevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors.Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy SeriesPharmacological management of osteogenesis.Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis.Direct Melanoma Cell Contact Induces Stromal Cell Autocrine Prostaglandin E2-EP4 Receptor Signaling That Drives Tumor Growth, Angiogenesis, and Metastasis.Understanding and targeting osteoclastic activity in prostate cancer bone metastases.Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma.Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumours.Denosumab in the prevention of skeletal-related events in patients with bone metastases from solid tumors: profile report.Tumor metastasis: moving new biological insights into the clinic.Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?Clinical efficacy of denosumab versus bisphosphonates for the prevention of bone complications: implications for nursing.Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression.Activation status of γδ T cells dictates their effect on osteoclast generation and bone resorption.Effects of toll-like receptors 3 and 4 in the osteogenesis of stem cells.Cancer pain physiology.The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials.Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone: A retrospective study.Breast cancer bone metastases: denosumab or zoledronic acid?
P2860
Q27015899-CEAF45D9-06A7-4740-A58C-9E5023CEF6C1Q30439048-D16ED052-34F6-43C2-8BA8-FF56162936EBQ30532494-7FAF4634-67B1-44BC-BF50-5D6E0EA443E5Q33729548-946BE45F-8CAC-456D-B1C0-561490F408BEQ36080739-FBD272FC-2B94-447C-8F40-DF02578121E0Q36218415-07CF2E1C-6A74-4326-86B0-74AC6B50AA7BQ36444308-D175CD45-A21B-4364-8C3D-FBB15BD7AE01Q36759374-D3790F8E-59FA-4129-AD10-1D2C3A219A75Q37187646-BCBEEF41-4972-4A4C-A1E1-047B716A56A7Q37215829-B7567042-7AA7-42FA-8BFD-9CD246768715Q37888670-C457AA87-8511-4234-98F3-0D73FBC0E386Q37952289-FE307E9A-FC96-4D11-B540-13A4FCDA936FQ38160740-7D4727CB-46F2-4824-A89B-0A237FA7F53EQ38282521-C6C6A4D2-FAA9-480B-B4AF-D5C8A30C66ABQ38571774-E9C5D623-EF35-48F4-8473-6C865B2C76C2Q39032864-99ECBEEA-D1E8-46E3-A7F5-4CB57FC1A726Q39428523-CD3ADD97-11D9-4485-AECF-88F9621D28CAQ40942283-40EDDC55-55F4-4B85-8EA3-A1411B6D2A60Q43100581-44239BBF-6D74-4F37-8E41-D3B4DC37A7DCQ43205303-12869D3A-EE4D-4E93-953E-30B056746069Q47132177-4F30BB0C-1FA5-4590-973A-509EAD8D4C4DQ53586132-B3B9B48B-D5E7-4637-BBDF-F61C07F89247Q58217182-5A3ABD45-C392-41DC-A5D0-6FBF7E183086
P2860
Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical development of anti-R ...... prevention of bone metastasis.
@en
Clinical development of anti-R ...... prevention of bone metastasis.
@nl
type
label
Clinical development of anti-R ...... prevention of bone metastasis.
@en
Clinical development of anti-R ...... prevention of bone metastasis.
@nl
prefLabel
Clinical development of anti-R ...... prevention of bone metastasis.
@en
Clinical development of anti-R ...... prevention of bone metastasis.
@nl
P1433
P1476
Clinical development of anti-R ...... prevention of bone metastasis.
@en
P2093
Allan Lipton
Carsten Goessl
P356
10.1016/J.BONE.2010.10.161
P577
2010-10-13T00:00:00Z